Information  X 
Enter a valid email address

IQ-AI Limited (IQAI)

  Print      Mail a friend

Wednesday 29 May, 2019

IQ-AI Limited

Issue of Convertible Loan Notes - Correction

RNS Number : 4902A
IQ-AI Limited
29 May 2019
 

IQ-AI LIMITED

("IQ-AI" or the "Company")

 

Issue of Convertible Loan Notes - Correction

 

The announcement released by IQ-AI earlier today has been amended to correct the number of Ordinary Shares into which the CLNs may convert and to correct the contact details for the Company. The amended text of the announcement is set out below. 

 

IQ-AI is pleased to announce that the Company has issued £250,000 in nominal amount of 6% unsecured convertible loan notes 2025, convertible into 16,666,666 ordinary shares of 0.1p each in the Company ("Ordinary Shares") at a price of 1.5 pence per share ("CLNs"). The funds raised as a result of the issue of the CLNs will be used to provide additional working capital for product development at the Company.

 

The CLNs have been subscribed for by Trevor Brown, Chairman of the Company.

 

Trevor Brown is directly and indirectly (through Free Association Books, a company in which he is interested) interested in 36,083,025 Ordinary Shares, equivalent to 29.98% of the issued ordinary share capital. Following the issue of the CLNs, Trevor Brown holds £796,926 of loan notes, directly and through Free Association Books.

 

The Directors of the Company accept responsibility for the contents of this announcement.

 

This announcement contains inside information as stipulated under the Market Abuse Regulations (EU) no. 596/2014 ("MAR").

 

 **ENDS**

 

For further information please contact:

 

IQ-AI Limited

Qu Li/Trevor Brown/Vinod Kaushal

Tel:  020 7469 0930

 



Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams and Fungai Ndoro

Tel: 020 7220 9797

 



 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
IODDMGZKGLLGLZM

a d v e r t i s e m e n t